Supplementary Digital Content 4. Characteristics of study at the end of follow-up, and follow-up period

| Treatment Variables | UFT | | | 5-FU | | |
|---------------------|-----|-----|-----|-----|-----|-----|
|                     | n   | %   | n   | %   | n   | %   |
| Total               | 14,486 | 63.39 | 8,366 | 36.61 | |
| Disease recurrence  |     |     |     |     |     |     |
| Without             | 12,916 | 89.16 | 20,485 | 73.66 | |
| With                | 1,570   | 10.84 | 7,324   | 26.34 | |
| Mortality           |     |     |     |     |     |     |
| Without             | 12,704 | 87.70 | 23,520 | 84.58 | |
| With                | 1,782   | 12.30 | 4,289   | 15.42 | |
| Gender              |     |     |     |     |     |     |
| Male                | 8,690  | 59.99 | 5,064  | 60.53 | |
| Female              | 5,796  | 40.01 | 3,302  | 39.47 | |
| Age (years ± SD)    | 69.23 ± 14.22 | 69.29 ± 14.16 |     |     |     |     |
| Insured premium (NT$) |     |     |     |     |     |     |
| <18,000             | 14,250 | 98.37 | 8,200  | 98.02 | |
| 18,000-34,999       | 192    | 1.33  | 131    | 1.57  | |
| ≥35,000             | 44     | 0.30  | 35     | 0.42  | |
| HTN                 |     |     |     |     |     |     |
| Without             | 10,218 | 70.54 | 5,967  | 71.32 | |
| With                | 4,268   | 29.46 | 2,399  | 28.68 | |
| DM                  |     |     |     |     |     |     |
| Without             | 11,611 | 80.15 | 6,679  | 79.84 | |
| With                | 2,875   | 19.85 | 1,687  | 20.16 | |
| COPD                |     |     |     |     |     |     |
| Without             | 13,541 | 93.48 | 7,826  | 93.55 | |
| With                | 945     | 6.52  | 540    | 6.45  | |
| CKD                 |     |     |     |     |     |     |
| Without             | 13,679 | 94.43 | 7,928  | 94.76 | |
| With                | 807     | 5.57  | 438    | 5.24  | |
| HHD                 |     |     |     |     |     |     |
| Without             | 12,996 | 89.71 | 7,544  | 90.17 | |
| With                | 1,490   | 10.29 | 822    | 9.83  | |
| CHD                 |     |     |     |     |     |     |
UFT, uracil-tegafur; 5-FU, 5-Flourouracil; HTN, hypertension; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; IHD, ischemic heart disease; CHD, congestive heart disease; CCI_R, Charlson comorbidity index removed cancer

| Years of follow-up | Treatment               | Min | Median | Max  | Mean ± SD   |
|--------------------|-------------------------|-----|--------|------|-------------|
|                    | Oral uracil-tegafur     | 0.01| 3.17   | 15.84| 4.10 ± 3.75 |
|                    | Injection 5-Flourouracil| 0.01| 3.07   | 15.92| 4.02 ± 3.67 |